Yang Kun, Dong Wenbin
Department of Newborn Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Front Pediatr. 2020 Oct 23;8:570247. doi: 10.3389/fped.2020.570247. eCollection 2020.
Bronchopulmonary dysplasia (BPD) is a chronic respiratory disease of preterm infants, associated with high morbidity and hospitalization expenses. With the revolutionary advances in microbiological analysis technology, increasing evidence indicates that children with BPD are affected by lung microbiota dysbiosis, which may be related to the illness occurrence and progression. However, dysbiosis treatment in BPD patients has not been fully investigated. Probiotics are living microorganisms known to improve human health for their anti-inflammatory and anti-tumor effects, and particularly by balancing gut microbiota composition, which promotes gut-lung axis recovery. The aim of the present review is to examine current evidence of lung microbiota dysbiosis and explore potential applications of probiotics in BPD, which may provide new insights into treatment strategies of this disease.
支气管肺发育不良（BPD）是一种早产儿慢性呼吸道疾病，与高发病率和住院费用相关。随着微生物分析技术的革命性进展，越来越多的证据表明，患有BPD的儿童受到肺部微生物群失调的影响，这可能与疾病的发生和发展有关。然而，BPD患者的失调治疗尚未得到充分研究。益生菌是已知的活微生物，因其抗炎和抗肿瘤作用，特别是通过平衡肠道微生物群组成来促进肠道-肺轴恢复，从而改善人类健康。本综述的目的是研究肺部微生物群失调的现有证据，并探索益生菌在BPD中的潜在应用，这可能为该疾病的治疗策略提供新的见解。
